











































Presumed Risk Factors and Biomarkers for Severe Respiratory
Syncytial Virus Disease and Related Sequelae
Citation for published version:
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators 2020, 'Presumed Risk Factors
and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an
Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe
(RESCEU)', The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaa239
Digital Object Identifier (DOI):
10.1093/infdis/jiaa239
Link:




The Journal of Infectious Diseases
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
Title page 
Page 1 of 24 
 
Running head:  
“RESCEU: Understanding RSV” 
 
Title:  
REspiratory Syncytial virus Consortium in EUrope (RESCEU): Presumed risk factors and biomarkers 




Kimberley Jefferies, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX3 7LE, UK 
Simon B Drysdale, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK and 
Department of Paediatrics, St George’s University Hospital NHS Foundation Trust, London, SW17 
0QT 
Hannah Robinson, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
Elizabeth Ann Clutterbuck, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
Luke Blackwell, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
Joseph McGinley, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
Gu-Lung Lin, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
Ushma Galal, Nuffield Department of Primary Care Health Sciences, Oxford, OX2 6GG 
Harish Nair, Usher Institute, University of Edinburgh, Old Medical School, Teviot Place, Edinburgh, 
EH8 9AG 
 
Page 2 of 24 
 
Jeroen Aerssens, Infectious Diseases, Janssen Pharmaceutica NV, 2340 Beerse, Belgium 
Deniz Öner, Infectious Diseases, Janssen Pharmaceutica NV, 2340 Beerse, Belgium 
Annefleur Langedijk, Department of Paediatrics, University Medical Center Utrecht, 3584 CX, The 
Netherlands 
Louis Bont, Department of Paediatrics, University Medical Center Utrecht, 3584 CX, The 
Netherlands 
Joanne G Wildenbeest, Department of Paediatrics, Immunology and Infectious Disease, Wilhelmina 
Children`s Hospitals, University Medical Center Utrecht, 3584 CX, The Netherlands 
Federico Martinon-Torres, Translational Paediatrics and Infectious Diseases, Pediatrics Department, 
Hospital Clínico Universitario de Santiago, Spain and Genetics, Vaccines, Infections and Pediatrics 
research group, Instituto de Investigación Sanitaria de Santiago, University of Santiago de 
Compostela, Spain 
Carmen Rodríguez-Tenreiro Sánchez, Translational Paediatrics and Infectious Diseases, Pediatrics 
Department, Hospital Clínico Universitario de Santiago, Spain and Genetics, Vaccines, Infections and 
Pediatrics research group, Instituto de Investigación Sanitaria de Santiago, University of Santiago de 
Compostela, Spain 
Simon Nadel, Department of Paediatrics, Imperial College, London, SW7 2AZ, UK 
Peter Openshaw, Faculty of Medicine, National Heart & Lung Institute, Imperial College, London, 
W2 1NY, UK 
Ryan Thwaites, Faculty of Medicine, National Heart & Lung Institute, Imperial College, London, W2 
1NY, UK 
Myra Widjojoatmodjo, Janssen Vaccines and Prevention B.V., 2333 CP Leiden, The Netherlands 
Linong Zhang, Sanofi Pasteur, Cambridge MA 02139, USA 
Thi Lien-Anh Nguyen, GSK Biologicals, 1330 Rixensart, Belgium 
 
Page 3 of 24 
 
Carlo Giaquinto, Fondazione PENTA ONLUS, Torre di Ricerca Pediatrica, Corso Stati Uniti, 4, 
35127 Padova, Italy 
Giuseppe Giordano, Fondazione PENTA ONLUS, Torre di Ricerca Pediatrica, Corso Stati Uniti, 4, 
35127 Padova, Italy 
Eugenio Baraldi, Fondazione PENTA ONLUS, Torre di Ricerca Pediatrica, Corso Stati Uniti, 4, 
35127 Padova, Italy 
Andrew J Pollard, Department of Paediatrics, Oxford Vaccine Group, Oxford, OX37LE, UK 
The RESCEU investigators 
 
Corresponding author 




Word count for abstract: 300 











Respiratory syncytial virus (RSV) is the leading viral pathogen associated with acute lower 
respiratory tract infection (ALRI) and hospitalisation in children under five years of age worldwide. 
Whilst there are known clinical risk factors for severe RSV infection, the majority of those 
hospitalised are previously healthy infants. There is consequently an unmet need to identify 
biomarkers that predict host response, disease severity and sequelae.   
Objectives: 
The primary objective is to identify biomarkers of severe RSV acute respiratory tract infection 
(ARTI) in infants. Secondary objectives include establishing biomarkers associated with respiratory 
sequelae following RSV infection and characterising the viral load, RSV whole-genome sequencing, 
host immune response and transcriptomic, proteomic, metabolomic and epigenetic signatures 
associated with RSV disease severity.  
Study design: 
630 infants will be recruited across three European countries; the Netherlands, Spain and the United 
Kingdom. Participants will be recruited into two groups. Group 1 will consist of infants with 
confirmed RSV ARTI (includes upper and lower RTIs), 500 without and 50 with co-morbidities.  
Group 2 will consist of 80 healthy controls.  
At baseline, participants will have nasopharyngeal, blood, buccal, stool and urine samples collected, 
plus complete a questionnaire and 14-day symptom diary.  At convalescence (7 weeks ± 1 week post 
ARTI) specimen collection will be repeated.  
Laboratory measures will be correlated with symptom severity scores to identify corresponding 
biomarkers of disease severity.  
Ethics and dissemination: 
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UK study authorisation has been granted from the Health Research Authority and ethics approval 
from NRES South Central and Hampshire A. In Spain this has been granted by Comité de Ética de la 
Investigación de Santiago-Lugo and in the Netherlands by the Medical Ethical Committee, UMC, 
Utrecht. All study procedures adhere to International Conference on Harmonisation Good Clinical 
Practice guidelines.  
ClinicalTrials.gov registration number: NCT03756766 
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INTRODUCTION 
Respiratory syncytial virus (RSV) is a major global health problem. It is the leading pathogen 
associated with acute lower respiratory tract infection (ALRI) and hospitalisation in infants [1] and 
contributes to about 13% of ALRI mortality in children younger than 5 years [2]. Premature birth, 
chronic lung disease, congenital heart disease, immunodeficiency and neuromuscular disease are 
among the known risk factors associated with severe RSV bronchiolitis [3–7]; however, the majority 
of hospitalised infants are previously healthy [8,9].  The clinical severity of bronchiolitis varies from 
mild forms manageable as an outpatient to severe cases requiring mechanical ventilation or 
extracorporeal membrane oxygenation (ECMO) in a paediatric intensive care unit (PICU) [10]. Two-
thirds of infants have an RSV infection in their first year of life [11], 2-3% of these infants will 
require hospitalisation [6,11–13] and 2-6% of these admissions need management in a PICU 
[9,11,13,14]. Access to mechanical ventilation and intensive care support has helped maintain a low 
mortality in high-income countries (0%–1.5% in otherwise healthy infants with RSV) [15]. However, 
globally, RSV is estimated to be responsible for approximately 118,200 deaths each year in children 
under 5 years of age [2]. There is also evidence that early life RSV infection results in chronic airway 
dysfunction, increased risk of subsequent wheezing episodes and asthma [16,17]. 
 
There remains a lack of a safe and effective treatment or prophylactic agent for RSV infection. 
Currently, the only option available is passive protection provided by the monoclonal antibody, 
palivizumab (Synagis®; Swedish Orphan Biovitrum AB [Sobi™]) [18–22]; however, its high cost 
limits its use to those deemed high risk for severe disease. Therefore, there is a parallel need to 
assemble clinical resources to identify the correlates of severe RSV disease for clinical management, 
classification of disease severity in clinical trials and identification of biomarkers for severe disease to 
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The objectives of this study are to establish biomarkers correlated with and/or predictive of RSV 
ARTI (including upper and lower RTIs) disease severity among infants (primary objective); to 
determine which biomarkers are associated with subsequent respiratory sequelae following primary 
RSV infection and to quantify the health care costs and interruption to normal activities of daily living 
(secondary objectives). The primary and secondary endpoints are listed in table 1. 
 
STUDY DESIGN 
This is a multi-national, multi-centre, case-controlled, observational study. 630 participants will be 
recruited across four sites including the University Medical Center Utrecht (UMCU), the Netherlands; 
Hospital Clínico Universitario de Santiago, Spain; Imperial College NHS Trust, London and 
participating hospitals in the Thames Valley and South Midlands Clinical Research Network 
(Oxford), UK. Infants will be recruited into two groups. Group 1 includes infants <12 months old 
with confirmed RSV ARTI, 500 without co-morbidities and 50 with co-morbidities (including 
congenital heart disease, bronchopulmonary dysplasia, prematurity defined as gestational age <37 
weeks, Down`s syndrome or any other significant medical condition) and Group 2 includes 80 healthy 
controls without RSV infection.  
Infants in Group 1 will be further subdivided into four groups for data analysis. Regular review of 
participants recruited will ensure the target recruitment numbers for each sub-group are met: 
1) Group 1a (n=250): healthy infants (without co-morbidities) with RSV infection requiring 
hospitalisation for at least 12 hours. Comparisons will be made between mechanically 
ventilated infants (severe phenotype) and those with less severe symptoms.  
2) Group 1b (n=250): healthy infants with RSV infection not requiring hospitalisation (ie: 
participants who remain in the community or who are discharged home within 12 hours of 
registration if they present to the emergency department). 
The analysis of Group 1a and 1b will answer the primary objective and the other groups will 
support the analysis of the secondary endpoints.  
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3) Group 1c (n=25): infants with RSV infection with any co-morbidity that would exclude them 
from group 1a and 1b requiring hospitalisation for at least 12 hours. 
4) Group 1d (n=25): infants with RSV infection with any co-morbidity that would exclude them 
from Groups 1a and 1b, and not requiring hospitalisation  
 
RECRUITMENT 
Potential participants for groups 1 and 2 will be recruited from both the hospital and community 
setting.  
Methods of recruitment will include: 
 Active surveillance: The clinical and research team working in the hospital setting 
(emergency department, paediatric ward, paediatric outpatient department or paediatric 
intensive care unit) identifying and approaching eligible participants.  
 Outreach to increase voluntary participation:  
o Poster advertising throughout local hospitals and general practitioner (GP) surgeries  
o Mail-out to health visitors and GPs to inform them of the study and encourage them 
to identify potential participants. 
o Media advertising through social media and website advertisement placed in 
locations relevant for the target age group with brief details of the study and contact 
details for further information. 
 For Group 1b, infants may also be recruited through the RESCEU birth cohort study in which 
children are actively followed in the first year of life.  
Potential participants will have the opportunity to contact their respective research sites for additional 
information by telephone or email.  
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ASSESSMENT OF ELIGIBILITY 
Formal assessment of trial eligibility will follow informed written consent. Eligible participants for 
Group 1 must fulfil the following criteria: 
- Male or female infant <12 months of age at enrolment. 
- Confirmed RSV positive ARTI. Confirmed using an RSV point of care test (either a rapid 
antigen detection test or rapid RSV PCR test) or a laboratory RSV PCR test.  
- Hospitalised for <48 hours at enrolment or within 96 hours of illness onset (for those not 
admitted). 
- Available for a 7 week (±1 week) convalescent visit. 
- Has not received medication to treat RSV infection (e.g.ribavirin), had no prior exposure to an 
RSV investigational vaccine or medication, has not received immunoglobulins or monoclonal 
antibodies (including palivizumab) or used oral steroids or montelukast within 7 days of 
enrolment. 
Group 2 (healthy controls) participants: 
- Cannot have had a respiratory illness or received a vaccination in the past 7 days 
- Must not have a history of a concurrent significant medical illness or have been born <37 
weeks gestation.  
(See supplementary table 1 for eligibility criteria for both groups) 
 
INFORMED CONSENT 
For both groups, consent will be obtained by a member of the research team who is suitably qualified 
and experienced and has been authorised by the chief or principal investigator. Parents or guardians 
will be provided with written and verbal versions of the study information booklet. This details the 
exact nature and rationale for performing the study, what is involved and the risks and benefits. They 
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must sign the latest approved version of the informed consent form before any study specific 
procedures are performed.  
For group 1, in some centres where RSV status is not determined as part of routine clinical care, 
initial consent will be obtained to perform a bedside RSV test. Only infants who have a confirmed 
RSV positive ARTI (either via a bedside test or diagnostic laboratory PCR test) are eligible for 
enrolment.  
For both consent steps, it is clearly stated that participation is voluntary and that the parent, guardian 
or legally authorised representative is free to withdraw their infant from the study at any time, for any 
reason without prejudice to future care, without affecting their legal rights and with no obligation to 
give the reason for withdrawal. They will be allowed as much time as required to consider the 
information, and the opportunity to question the investigator, their GP or other independent parties 
before deciding whether to participate.  
Additional informed written consent will be obtained for storage of participants samples in local 
biobanks for future studies.  
 
STUDY PROCEDURES AND SCHEDULES FOR DATA COLLECTION  
GROUP 1- active RSV ARTI 
After informed written consent has been obtained and RSV positive ARTI confirmed, enrolled 
participants will undergo sampling. This will include two nasopharyngeal swabs, one synthetic 
absorption matrix (SAM) swab [25] or buccal swab, venepuncture and collection of a stool and urine 
sample. Participants’ parents or guardians will also be asked to complete a baseline questionnaire 
(supplement 2) and a 14-day respiratory symptom diary (supplement 3). For those being treated as an 
inpatient, daily nasopharyngeal swabs will be collected until discharge to monitor the kinetics of RSV 
viral load.  
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Participants will subsequently have a convalescent visit at 7 weeks (±1 week) after discharge from 
hospital, or post onset of symptoms for participants recruited in the community and not admitted to 
hospital. This will be followed by annual questionnaires (supplement 4 and 5), sent via mail or email, 
to assess respiratory symptoms and sequelae and determine health care costs, resource use and Health 
Related Quality of Life (HRQoL) data (Group 1 study overview can be seen in figure 1). 
 
Baseline participant information  
For group 1 participants, baseline information will be collected either in the hospital or community 
setting. Information collected will include patient demographics, medical advice sought, medical 
history, clinical examination findings, laboratory or radiological investigations and treatment 
received. A standardised respiratory clinical severity score (ReSVinet score [26]) will also be 
calculated. This records details such as feeding intolerance, medical intervention required, respiratory 
difficulty, respiratory frequency, presence of apnoea, overall condition and presence of fever [26]. 
 
Baseline questionnaire and 14-day respiratory symptom diary 
Group 1 participants will complete a baseline questionnaire to collect information about household 
demographics, attendance at nursery or child-minders, family history of atopy (asthma/eczema/hay 
fever), exposure to household smoke or pets and a baseline assessment of quality of life.  
The 14-day respiratory symptom diary will also be initiated at baseline and completed either online or 
as a paper copy. If a paper source document is used, data will be entered into the electronic data 
capture system (REDCap) by the clinical research team.  
Data captured in the daily diary includes whether the respiratory symptoms are ongoing, what 
symptoms are present (cough, coryza, wheeze, shortness of breath, feeding difficulties and 
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temperature), the infants overall health and the health and wellbeing of their parents, guardians or 
legal representatives.  
At the convalescent visit (7 weeks ±1 week post ARTI) a member of the clinical research team will 
ensure the baseline questionnaire and 14-day diary has been completed and entered into REDCap.  
 
Procedures & sampling 
At baseline, group 1 participants will have two nasopharyngeal swabs taken (one in M4RT transport 
medium and one in Amies transport medium) and a SAM swab [25] (site dependent) for RSV 
confirmation and viral load, PCR for other respiratory viruses and microbiome and transcriptomic 
analysis. These samples can also be obtained from a nasopharyngeal aspirate if taken as part of 
routine clinical care. If the child is intubated and ventilated and has a bronchoalveolar lavage done as 
part of their clinical care, a sample will also be taken for analysis.  
Venous blood samples will be obtained at a maximum volume of 0.8ml/kg. Samples will be collected 
into Paxgene RNA (0.2-0.5ml) tubes for transcriptomic analysis, serum tubes (≥1.8ml) for proteomic, 
metabolomic, systems serology, RSV proteins F, Ga, Gb and N and pre-F and post-F neutralising 
antibody analysis; serum clot or EDTA and buccal samples for epigenetic and genome-wide 
association study (GWAS) analysis and lithium heparin tubes (≥ 1-2ml) to obtain whole blood for 
cellular immunology (includes flow cytometric cell phenotyping and intracellular cytokine staining). 
The stool specimen will be analysed for microbiome and the urine for metabolomics.  
 
Annual questionnaires 
Questionnaires will be sent to participants’ parents or guardians at the first, second and third 
birthdays, for a maximum of 3 years depending on the recruitment date in relation to the study end 
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date. Contact will be made via telephone, text or email and the questionnaire will be distributed via 
email or mail each year.  
The questionnaire determines whether the child has had any respiratory symptoms, including wheeze, 
since the original RSV illness, whether they sought advice from a healthcare professional, what 
treatment they received (e.g. antibiotics, inhaled bronchodilator or corticosteroids), duration of 
symptoms and frequency of recurrence. It also includes information on the presence of atopy, 
household smoke exposure and whether the child received their routine vaccinations.  
 
GROUP 2- Healthy controls 
For Group 2 participants, baseline samples will include up to two nasopharyngeal swabs, a SAM swab 
or buccal swab, venous bloods, a stool specimen and a urine specimen. These specimens will be tested 
as for the Group 1 participants. A week after enrolment the participants’ parents or guardians will be 
contacted to ensure the participant has remained well and free from respiratory symptoms. If they 
have developed symptoms in this time period another participant will be recruited as a replacement.  
Participants will subsequently receive annual questionnaires as for group 1.  
Details of sampling procedures and data collection for Groups 1 and 2 can be found in supplement 6.  
 
SPECIMEN PROCESSING 
Specimens will undergo initial processing in local laboratories to enable storage until being 
transferred to the appropriate sites for final processing and analysis. This includes industry partners of 
the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
(e.g.GlaxoSmithKline, Sanofi Pasteur, Janssen Pharmaceuticals and AstraZeneca) who are members 
of the RESCEU project, Fondazione PENTA for the treatment and care of children with HIV-ONLUS 
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(PENTA) and academic sites which include the University of Oxford and the University Medical 
Centre Utrecht (UMCU). Further details of sample processing can be found in supplement 7.  
 
ADVERSE EVENTS DEFINITION AND REPORTING  
The International Conference on Harmonisation (ICH) definition of a serious adverse event will be 
used. No medicinal products will be administered during this observational study. Participants will 
only have venepuncture and the collection of nasopharyngeal, buccal, urine and stool samples, hence 
reporting of serious adverse events (SAEs) will be limited to those relating directly to the collection of 
research samples or death regardless of cause.  
Should an SAE occur to a participant, during or immediately after the visit, it will be reported to the 
local Principal Investigator (PI) and subsequently to the Chief Investigator (CI) within 24 hours of the 
study staff being aware of the SAE. 
The local investigators opinion will be used to determine whether the event was ‘related’ to the 
research procedures. The CI will determine whether ‘related’ events are expected or unexpected in 
relation to those procedures. Where the CI deems an SAE to be ‘related’ and ‘unexpected’ the SAE 
will be reported to the Research Ethics Committee. 
 
TRIAL MONITORING 
Site specific trial monitoring will be in place according to Good Clinical Practice (GCP) guidelines. 
Following written Standard Operating Procedures, the monitors verify that the clinical trial is 
conducted and data generated, documented and reported in compliance with the protocol, GCP and 
applicable regulatory requirements.  
 
SAMPLE SIZE CALCULATON 
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The consortium-wide, sample size estimation is based on a microarray analysis of the primary outcome 
comparing disease severity in group 1a and 1b participants, and assuming a binary biomarker 
(biomarker positive or biomarker negative). Biomarkers were deemed to be predictive if an odds ratio 
of at least 1.2 (log odds=0.18, mean difference=0.2) for the biomarker presence/absence between the 
severe RSV sample and the non-severe RSV controls was recorded. Using RSV PCR, 226 otherwise 
healthy infants with severe RSV disease requiring hospitalisation and 226 age- and sex-matched cases 
with RSV not requiring hospitalisation will be recruited to achieve 90% power (SD 0.4) to detect a log 
odds ratio of 0.18 (mean difference=0.2) with a true biomarker rate of 0.5% and a False Discovery Rate 
(FDR) of 5%. This is estimated using a two-sided Mann-Whitney U or Wilcoxon Rank-Sum test 
assuming that the actual data distribution is logistic. We plan to recruit 10% over these numbers to 
account for anticipated drop out for a sample size of 500. Groups 1c, 1d and 2 are exploratory cohorts.   
 
STATISTICS AND ANALYSIS PLAN  
Individual datasets obtained from different endpoints (e.g. GWAS, metabolomics, proteomics, 
transcriptomics) will be analysed separately in association with the RSV disease severity. With the 
availability of nasal microbiome data, we will also analyse the interaction between bacterial species 
colonizing the nasopharynx and disease severity and the clinical outcome. 
Additionally, large data sets will be investigated for integrative computational analyses in order to 
identify biomarker profiles associated with differing disease severity, in the context of biomarker 
discovery. Specificity of the results will be tested against 1) existing literature and publicly available 
data, 2) ongoing prospective and observational RESCEU studies designed to be used for biomarker 
validation (i.e. infant birth cohort, older-adults cohort, COPD cohort), 3) analysis of existing validation 
datasets that RESCEU has access to (i.e. Danish Neonatal Screening Biobank, existing data from a 
prospective study in Kilifi, Kenya, adult challenge studies, and the MOSAIC study) further details are 
available at http://resc-eu.org/. The biomarker validation will be performed with the consideration of 
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population groups (by age: infants, older-adults; by susceptibility: COPD subjects; by location) and 
disease severity measures (RSV severity, clinical variables). 
For correlates of disease severity, various sources of biomarker data (e.g. transcriptomic, metabolomic 
and proteomic data) will be used for predictive modelling. The challenge of integrating different data 
types (e.g.virology, immunology, transcriptomic, metabolomic and proteomic) will be tackled by 
investigating and considering different methods for the integration of the multi-omics data (25). Feature 
selection will be examined with well-established algorithms including support vector machines, random 
forest or nearest shrunken centroid classifiers, as well as more recent methods such as elastic net 
regularization, and with extensive inner cross-validation approaches, such as x-fold or LOOCV.  
Provided the sample size is sufficient for each of the nasal microbial endpoints and there is evidence of 
a relationship between nasal microbiota and RSV severity, increased depth analysis will be performed 
using relevant methods described above. 
 
REGULATORY APPROVALS AND TRIAL REGISTRATION  
Study recruitment commenced in October 2017 and is currently ongoing. Within the UK, study 
authorisation has been granted from the Health Research Authority (IRAS project ID: 231136) and 
Research Ethics Committee (REC) approval has been granted by South Central and Hampshire A 
(NRES reference 17/SC/0522). In Spain this has been granted by Comité de Ética de la Investigación 
de Santiago-Lugo (2017/395) and in the Netherlands by the Medical Ethical Committee, UMC, 
Utrecht (reference17/563).  
 
ETHICS AND DISSEMINATION  
The investigator will ensure the study is conducted in accordance with the principles of the 
declaration of Helsinki, relevant regulations and with GCP. The study staff will ensure that the 
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participants’ anonymity is maintained. The study will comply with the data protection act so 
participants are anonymised and only identified with a participant ID. All documents will be stored 
securely and only accessible by study staff and authorised personnel.  
The samples obtained are intended to be used solely for research and not for diagnostic purposes. In 
the case of an incidental abnormal finding, the results will be discussed with the responsible clinical 
team who will discuss the implications with the participants. Venepuncture can be moderately painful 
but pain reducing methods will be offered prior to the procedure (eg: anaesthetic cream or sucrose) 
and bruising may occur. If the first attempt is unsuccessful, further attempts will be made if verbal 
consent is obtained from the participants’ parent/carer or legal guardian. Nasopharyngeal swabs can 
cause brief discomfort but the procedure lasts less than 10 seconds and is performed by trained 
personnel. Nose bleeds are possible but uncommon. Obtaining the stool and urine sample will cause 
no discomfort.  
 
PUBLICATION 
The investigators will be involved in reviewing drafts of the manuscripts, abstracts and any other 
publications arising from the study. Participants are not given individual results but will have access 
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Table 1: Primary and Secondary Endpoints 
 Sampling procedures and outcome measures 
 Group 1 (RSV positive ARTI cases, 
both hospitalised and non-hospitalised) 
Group 2 (healthy controls without RSV) 
Primary Endpoints   
To establish biomarkers correlated with or 
predictive of RSV disease severity in infants  
(Primary analysis will compare healthy 
infants (without co-morbidities) with RSV 
infection requiring hospitalisation for at least 
12 hours (Group 1a) with healthy infants with 
RSV infection not requiring hospitalisation/ 
discharged home within 12 hours of 
registration in the emergency department 
(Group 1b) 
- At enrolment: nasopharyngeal swabs (microbiome, transcriptome, viral PCR), buccal swab, blood 
(transcriptomics, pre/post-F RSV antibodies, metabolomics, flow cytometry, cellular immunology), 
urine (metabolomics), stool (microbiome) sampling. 
- At convalescence (7 weeks ±1 week post 
ARTI) all of the above samples are repeated 
(group 1 only) 
 -Severity of ARTI assessed using the 
ReSVinet score* and the need for 
hospitalisation. 
 
Secondary Endpoints   
To establish biomarkers associated with 
sequelae following RSV infection in infants 
- At enrolment: Analysis of nasopharyngeal swabs (microbiome, transcriptome, viral PCR), buccal 
swab, blood (transcriptomics, pre/post-F RSV antibodies, metabolomics, flow cytometry, cellular 
immunology), urine (metabolomics) and stool (microbiome) samples. 
-At convalescence (7 weeks ± 1week post 
ARTI) the above samples will be repeated 
(Group 1 only) 
 
- Sequelae determined from parental questionnaires completed at 1, 2 and 3 years of age  
To characterise the viral load and genetic 
sequence of RSV associated with mild and 
severe disease  
- At enrolment: nasopharyngeal sampling (viral load, multiplex PCR, RSV sequencing) 
-Daily nasopharyngeal swabs for hospitalised 
participants  
- At convalescence (7 weeks ± 1 week post 
ARTI) samples repeated.  
-Illness severity assessed using the ReSVinet 
score* and the need for hospitalisation.  
 
To characterise the immune response to mild 
and severe RSV disease  
-At enrolment: blood samples for cellular immunology (flow cytometric cell phenotyping and 
intracellular cytokine staining), systems serology, presence and characteristics of pre and post-F 
neutralising antibodies 
-At convalescence (7 weeks ± 1 week post 
ARTI) blood samples repeated 
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 -Illness severity assessed using the ReSVinet 
score* and the need for hospitalisation. 
To determine health care costs, health care 
resource use, interruption of normal activities, 
and Health Related Quality of Life in RSV-
associated ARTI patients and their families 
 
- Baseline questionnaire** at enrolment  
- Annual questionnaires**, maximum 3 years (to quantify number of hospital admissions, number of 
days admitted and other healthcare advice sought and how often)  
- 14-day symptom diary** during illness 
(Group 1 only)- to quantify duration of hospital 
stay and symptoms. 
 
(** baseline and annual questionnaires, as well as the 14-day symptom diary will elicit HR-QoL and the impact of RSV related ARTI with Group 2 
responses acting as controls. These questionnaires will be completed by the parents or legal guardians and have been designed specifically for this study- 
see supplementary information for details) 
(ARTI includes both upper and lower respiratory tract infections). * The ReSVinet scale [26]. PLoS ONE 2016; 11(6): e0157665. 
doi:10.1371/journal. pone.0157665 
 
